Supernus Pharmaceuticals SUPN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| APOKYN | $40.52M-15.2% | $47.77M-18.1% | $58.3M-14.0% | $67.78M-6.2% | $72.25M-2.3% | |
| Collaboration revenue (ZURZUVAE) | $80.64M+52.2% | $53M+163% | $20.16M— | $0— | —— | |
| GOCOVRI | $151.38M+3.1% | $146.82M+1.2% | $145.1M+3.7% | $139.91M+3.7% | $134.95M+3.2% | |
| ONAPGO | $25.63M+48.5% | $17.25M+105% | $8.41M+424% | $1.6M— | $0— | |
| Other | $23M-14.5% | $26.91M-7.5% | $29.09M-0.9% | $29.36M-3.3% | $30.37M+4.7% | |
| Oxtellar XR | $37.92M-6.8% | $40.7M-13.5% | $47.05M-27.4% | $64.84M-21.6% | $82.72M-16.8% | |
| Qelbree | $317.75M+4.3% | $304.65M+2.2% | $298.12M+6.8% | $279.07M+7.0% | $260.92M+8.1% | |
| Royalty, licensing, and other revenues | $60.89M+54.5% | $39.42M+49.0% | $26.46M-7.0% | $28.45M+6.2% | $26.77M+11.0% | |
| Trokendi XR | $39.1M-7.8% | $42.42M-13.2% | $48.85M-9.7% | $54.12M-9.8% | $60.01M-5.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Supernus Pharmaceuticals break its business down?
- Supernus Pharmaceuticals (SUPN) reports total revenues by product across 9 parts — APOKYN, Collaboration revenue (ZURZUVAE), GOCOVRI, ONAPGO and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Supernus Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Supernus Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.